Study: Rushing FDA approvals might compromise drug safety

Harvard University researchers found drugs the FDA cleared shortly before its deadline are more prone to safety problems than those approved with time to spare. The FDA said it does not grant approval unless it is ready. It "has the option of denying approval altogether if there is any question about safety," said Janet Woodcock, head of the agency's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal (free content), The · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC